Parliament, Amnesty International, NHS staff, and health workers' protests have combined to put Palantir's £330 million NHS contract on a clock counting down to February 2027.
The coalition of forces now aligned against Palantir's presence in the NHS is not just politically inconvenient. It is structurally significant, and any enterprise AI company currently pitching government healthcare contracts across the UK or Europe should be reading it that way. In early June 2026, the House of Commons Science, Innovation and Technology Committee recommended that the government use the February 2027 break clause to exit the £330 million Federated Data Platform contract, going further and calling for a British alternative. The committee stated plainly that Palantir "should not have such a significant role in the UK public sector." Amnesty International backed the call the same day.
The £330 million contract was awarded in 2023 under the Conservative government, giving Palantir a seven-year mandate to build and run a unified data platform for NHS England. The February 2027 date is not a deadline so much as a narrowing window: Health Minister Zubir Ahmed has said the government will examine the break clause if other providers can do the job better, and ministers are now under pressure to make a decision before that option disappears. The mechanics of a potential exit are already being studied, which says something about how seriously the government now treats the criticism.
On the ground, resistance has moved well past protest signs. NHS analytics staff are boycotting the Federated Data Platform. One senior NHS official described Palantir publicly as "ethically bankrupt" and said colleagues were deliberately slowing their use of the system when required to log in. According to the Financial Times, at least one NHS official who questioned the platform's value at his own trust received a phone call from a senior official threatening his job. That kind of internal pressure, aimed at suppressing legitimate professional feedback, tends to harden opposition rather than quiet it. The British Medical Association has passed a resolution calling for doctors to stop using the system entirely.
The formal parliamentary case against Palantir runs through several specific concerns, none of which are about whether the software technically works. The committee pointed to Palantir's contracts supplying software to the Israeli military and intelligence services, its role in US Immigration and Customs Enforcement deportation operations under the Trump administration, the opacity of patient data access arrangements, and Peter Thiel's political profile. Amnesty International was explicit: Palantir has been supplying software to Israeli military and intelligence services in connection with operations in Gaza. These are not abstract concerns for NHS staff treating patients who hold strong views on those issues.
This is the combination that enterprise AI companies need to study. Any single element, a controversial founder, a government surveillance contract, an opaque data arrangement, might be manageable in isolation. Together, they have created a legitimacy gap that no product improvement closes. Health workers and campaigners protested outside Palantir's London offices during a closed-door NHS strategy meeting organized by Medact and Health Workers for a Free Palestine. When the frontline users of an enterprise system become its most vocal opponents, the commercial case for that system starts to erode regardless of what the contract says.
Palantir's financial position complicates any clean narrative about the NHS situation inflicting real damage. Revenue for Q1 2026 surged 85% to $1.633 billion, and investors have had little reason to treat the NHS review as a material earnings shock. The direct revenue exposure is modest: £330 million across seven years works out to roughly £47 million annually, a small fraction of Palantir's expected annual revenue. Investors are not wrong to be calm about the number.
But the NHS contract was never just a revenue line. It was a proof point for Palantir's thesis that Western governments would place their most sensitive public data infrastructure in the hands of a US company with a surveillance pedigree. If that thesis collapses in the UK, it becomes harder to advance in Germany, France, or any EU market already cautious about American data sovereignty. The committee's specific recommendation, to find a replacement "developed by UK-owned and UK-based providers that are more compatible with UK values," signals a procurement doctrine that other governments may adopt. That is the risk worth pricing, and right now it is not fully in the model.
Also read: Software Stocks Are Posting Record Earnings While Investors Price In Their Obsolescence • LG Electronics is bringing its $65 billion hardware business to Arbitrum to build an advertising platform that puts the entire ad supply chain on-chain • Abridge is becoming the operating system for medicine after landing Eli Lilly equity and a clinical foundation model deal with NVIDIA
